产品说明书

PK11007

Print
Chemical Structure| 874146-69-7 同义名 : -
CAS号 : 874146-69-7
货号 : A1213296
分子式 : C15H11ClFN5O3S2
纯度 : 98%
分子量 : 427.861
MDL号 : MFCD07427349
存储条件：

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 250 mg/mL(584.3 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 The tumor suppressor p53 is a key mediator in cell cycle arrest, DNA repair, and apoptosis. PK11007 is a mild thiol alkylator that shows anticancer activity towards p53-compromised cell lines. Incubation of stabilized full-length p53 with 1mM PK11007 for 2 h did not affect the binding of p53-GADD45a and the Kd value was 33.7nM. Treatment with PK11007 at 15-30µM markedly reduced cell viability in mutant p53 cell lines MKN1 (V143A), HUH-7 (Y220C), NUGC-3 (Y220C), and SW480 (R273H/P309S). PK11007 reduced cell viability of p53 WT cancer cell lines (HUH-6 and NUGC-4) and fibroblast cell line WI-38 only at high concentrations (60 and 120µM). The downregulation of p53 protein expression by siRNA did not alter PK11007-mediated viability reduction in HUH-6 and HUH-7 cells. In MKN1 cells (p53-V143A), PK11007 at 15 and 20µM resulted in a significant viability difference between wild-type and p53-/- cells. The protein levels of p53 target genes, including p21, MDM2, and PUMA, were upregulated by PK11007 (15, 30, and 60µM) in NUGC-3 (p53-Y220C), HUH-7 (p53-Y220C), and MKN1 (p53-V143A) cells. PK11007 (15, 30, and 60µM) also dose-dependently upregulated the protein level of spliced XBP-1, a key marker for the activation of unfolded protein response, in HUH-7 cells[1]. PK11007 inhibited the proliferation of a panel of 17 breast cell lines with IC50 values varied from 2.3 to 42.2μM[2].
作用机制 The alkylation of the surface-exposed redox-sensitive cysteines (i.e. C182 and C277) by PK11007 stabilizes the DNA-binding domain of p53 in vitro without compromising its DNA-binding affinity[1].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.34mL

0.47mL

0.23mL

11.69mL

2.34mL

1.17mL

23.37mL

4.67mL

2.34mL
参考文献

[1]Bauer MR, Joerger AC, Fersht AR. 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells. Proc Natl Acad Sci U S A. 2016;113(36):E5271-E5280. doi:10.1073/pnas.1610421113

[2]Synnott NC, Bauer MR, Madden S, et al. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. Cancer Lett. 2018;414:99-106. doi:10.1016/j.canlet.2017.09.053